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Antigen presenting cellMHC class II (MHC-II)molecules function by binding peptides derived from either self or foreign proteins and ex-
pressing these peptides on the surface of antigen presenting cells (APCs) for recognition by CD4 T cells. MHC-II is
known to exist on clusters on the surface of APCs, and a variety of biochemical and functional studies have sug-
gested that these clusters represent lipid raft microdomain-associated MHC-II. This review will summarize data
exploring the biosynthesis of raft-associated MHC-II and the role that lipid raft association plays in regulating T
cell activation by APCs. This article is part of a Special Issue entitled: Nanoscale membrane organisation and
signalling.
Published by Elsevier B.V.1. Introduction
Glycosphingolipid-, sphingomyelin-, and cholesterol-enriched lipid
raft membrane microdomains reside on the plasma membrane and
throughout the secretory and endocytic membranes of eukaryotic cells
[1]. Lipid rafts are dynamic structures, are approximately 4 to 200 nm
in diameter [2], and have been implicated in a variety of cellular events
including signal transduction, endocytosis, vesicular transport, and
cell adhesion [3,4]. Biochemically, rafts are “deﬁned” as detergent-
resistant membrane microdomains; this is based on their relative insolu-
bility in mild nonionic detergents at low temperature (e.g. Triton X-100)
and rafts (and raft-associated proteins) can be isolated using discontinu-
ous sucrose density gradient centrifugation [5]. This “deﬁnition” has a
number of caveats that revolve around the potential that detergent
extraction per se “creates” lipid rafts [6,7]; these will be dealt with else-
where in this issue. A diverse array of plasma membrane proteins is de-
tected in lipid rafts either constitutively [8], or more commonly, after
ligand-induced receptor clustering. Treatment with cholesterol-binding
compounds that perturb lipid raft integrity can impact raft-associated
membrane protein's functions [9]. The ability of proteins to become
(and maintain) raft associated thus has important implications in under-
standing the coordination of a wide variety of cellular events.le membrane organisation and
alth; Building 10, Room 4B36,
1 301 435 7923.Professional antigen presenting cells (APCs, including dendritic cells
(DCs), macrophages, B cells, and certain epithelial cell types) generate
peptide fragments of internalized protein antigens, and these peptide
fragments in turn bind MHC-II molecules in lysosome-like antigen pro-
cessing compartments [10]. Peptide binding to MHC-II in these com-
partments results in either constitutive or inducible transport of the
molecules to the cell surface, depending upon the APC subtype. Once
at the plasma membrane, speciﬁc peptide–MHC-II (pMHC-II) com-
plexes interact with peptide-speciﬁc CD4 helper T cells and induce
antigen-speciﬁc T cell activation, proliferation, generation of immuno-
logical memory, and stimulate production and secretion of a variety of
cytokines. The recognition of pMHC-II complexes by T cells forms the
basis of the adaptive immune response and there is considerable evi-
dence that lipid rafts (both on APCs and on CD4 T cells) play an impor-
tant role in antigen presentation. In this review we will discuss the
evidence for lipid raft microdomain-mediated clustering of MHC-II,
the biosynthesis of lipid raft-associated pMHC-II complexes, and the
role that lipid rafts play in facilitating antigen presentation to T cells
for the initiation of adaptive immune responses.
2. A history of MHC-II lipid rafts
Electron microscopy, ﬂuorescence resonance energy transfer, and
confocalmicroscopy imagingﬁrst suggested thatMHC-II is not evenly dis-
persed on lymphocytes, but instead a portion of the molecules are clus-
tered on the plasma membrane [11–13]. The ﬁrst indication that MHC-II
was associated with membrane rafts came from MHC-II antibody cross-
linking studies in a macrophage cell line that revealed cross-linking in-
duced intracellular tyrosine kinase activity togetherwith increased ability
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the cholesterol chelating agent methyl-β-cyclodextrin (MCD) prevented
MHC-II raft association and tyrosine kinase activity, leading the authors
to conclude that antibody-induced clustering of MHC-II initiated signal
transduction via plasma membrane rafts [14]. Confocal ﬂuorescence mi-
croscopy analysis conﬁrmed MHC-II raft association after cross-linking
[14,15], since the clusters co-localized with cholera toxin B subunit, a
commonly used lipid raft marker that binds GM1 glycosphingolipids.
We have recently shown that treatment with MCD leads to a re-
distribution of MHC-II on the surface of DCs such that the molecules no
longer have a clustered distribution, thereby supporting the idea that
these clusters represent lipid raft-associated MHC-II [16].
Subsequent to the study of Huby et al. [14], a number of laboratories
have shown that a substantial fraction of MHC-II is constitutively lipid
raft-associated in APCs. MHC-II is present in lipid rafts isolated from a
wide variety of human and mouse APC subtypes including transformed
B cells lines [17–19], primary tonsil B cells [20], monocytes [20–22], and
DCs [16,23–25]. In each of these studies cross-linking was not required
to reveal MHC-II lipid raft association, and as is found for many raft
“resident” proteins, it is likely that cross-linking simply stabilizes
MHC-II/lipid raft associations that constitutively exist. The inconsistency
in the literature regarding the extent to which MHC-II (or other
molecules) associateswith lipid rafts is likely due to the raft isolation pro-
cedure itself. The amount of MHC-II detected in lipid rafts varies and is
critically dependent on a variety of experimental factors including tem-
perature, the detergent used, the ratio of protein-to-detergent in the
cell lysate, and even the serum type [18,26]. We have found that in
the mild detergent Brij-58 more than 70% of MHC-II on mouse DCs
is lipid raft associated, however when the same number of DCs is
lysed instead in an equivalent volume of Triton X-100 this value
drops to 10%. Similarly, small numbers of DCs solubilized in a given
volume of lysis buffer show less apparent lipid raft association as
compared to a large number of DCs lysed in this same volume of buff-
er (PAR, unpublished data). By biotinylating surface proteins on ice
we have found that more than 50% of cell surface MHC-II molecules
are lipid raft associated in human and mouse B cell lines [17]. In all
of our studies we are careful to ensure that sufﬁcient detergent was
added to completely solubilize “non-raft” proteins (such as ICAM-1
and calnexin), giving us conﬁdence that a value greater than 50% ac-
curately represents the “average” extent of lipid raft association of
MHC-II on the surface of APCs.
3. The biosynthesis of the MHC-II lipid raft
MHC-II acquires its peptide fragments in late endosomal/
pre-lysosomal antigen processing compartment following degradation
of internalized proteins [10]. The ability of newly synthesized MHC-II
to trafﬁc to these intracellular compartments is dependent on MHC-II
association with a chaperone protein termed as the Invariant chain
(Ii). Ii binds MHC-II α- and β-chains shortly after synthesis in the
endoplasmic reticulum, and dileucine sortingmotifs present in the Ii cy-
toplasmic tail direct the MHC-II–Ii complex to endosome/lysosomes
[27]. Once in these compartments Ii is degraded and dissociates from
MHC-II, antigenic peptides bind to Ii-free MHC-II, and functional
pMHC-II complexes are transported to the plasma membrane. Pulse-
chase biosynthetic labeling studies using [35S]methionine [28] and
intracellular transport inhibition studies using Brefeldin A [29] indicate
that MHC-II–Ii complexes ﬁrst become lipid raft-associated during tran-
sit through the Golgi apparatus. Up to 60% of newly synthesizedMHC-II
remain lipid raft-associated during the processes of Ii removal, peptide
binding, and pMHC-II transport to the cell surface [28,29].
The lysosome-like antigen processing compartments in APCs usually
have a multi-vesicular morphology and represent what is known in
non-APCs as multivesicular bodies (MVBs). The intraluminal vesicles
(ILVs) in the MVB are approximately 50 nm in diameter and contain
many of the lipids associated with rafts including cholesterol,sphingomyelin, and gangliosides [30,31]. Using the cholesterol-
binding toxin perfringolysin-O Mobius et al. have shown that the MHC-
II-positive ILVs of MVB possess large amounts of raft lipid membranes
[32]. Since the ILVs of MVB are likely to be the site of peptide-loading
onto MHC-II, it has been proposed that these vesicles “back-fuse” with
the MVB limiting membrane prior to vesicle-mediated transport of
pMHC-II to the plasma membrane of APCs [33]. A hypothetical model
depicting the steps involved in back-fusion of ILV “raft” with the MVB
limiting membrane and budding, docking, and fusion of pMHC-II raft
vesicles with the plasma membrane is shown in Fig. 1. Occasionally,
the intactMVB fuses directlywith the plasmamembrane of cells, thereby
liberating the intraluminal vesicles into the extracellular space. These se-
creted vesicles, termed exosomes, are released by a variety of cell types
and have been reported to serve a variety of distinct functions [34]. The
MHC-II present on isolated exosomes is relatively detergent-insoluble
[31], a ﬁnding that is in agreement with the idea that exosome-
associatedMHC-II is present in lipid rafts. WhileMHC-bearing exosomes
secreted from APCs can stimulate both CD4 and CD8 T cells [35–37],
the signiﬁcance of exosomes as “mini-APCs” in vivo still needs to be
determined.4. Linking lipid rafts to efﬁcient pMHC-II expression on the
APC surface
The demonstration that MHC-II becomes lipid raft-associated in the
Golgi apparatus, before Ii dissociation and peptide binding in endo/lyso-
somes, has allowed us to generate a model describing howMHC-II lipid
raft association may enhance the ability of APCs to present pMHC-II
complexes to CD4 T cells. It is known that newly synthesized MHC-II
molecules consist of three pairs of MHC-IIαβ dimers assembled around
a core of trimeric Ii molecules [38], and it is also known that this nine-
chainMHC-II–Ii complex is already lipid-raft associated before its arrival
in lysosome-like antigen processing compartments [28]. Following Ii
degradation and dissociation from the MHC-II–Ii complex, the three
liberated peptide-freeMHC-IIαβ dimerswould be predicted to dissem-
inate by diffusion.We speculate that upon removal of Ii, the threeMHC-
II αβ dimers remain “associated” due to their localization to the same
lipid raft (Fig. 2). This model further predicts that newly-liberated
MHC-II αβ dimers would be likely to acquire the same antigenic pep-
tides in these compartments, be transported to the plasma membrane,
and at the cell surface remain associated with the same lipid raft. The
dissociation and re-association of MHC-II at the cell surface would be
predicted to result in a “mixing” of raft protein components and lead
to a more heterogeneous lipid raft, thus diluting any single peptide de-
terminant on MHC-II.
One prediction of any model proposing that lipid raft association is
important for MHC-II function in APCs is that there is insertion of a
“quantum” of identical pMHC-II into the plasma membrane of APC
after pMHC-II complex formation in antigen processing compartments.
We have recently obtained evidence that clusters of speciﬁc pMHC-II
complexes generated in late endosomes and remain clustered in lipid
rafts with the same peptide at the cell surface [16]. Using confocal
immunoﬂuorescence microscopy, DCs pulsed with HEL protein ﬁrst
generate MHC-II-HEL(46–61) complexes with MHC-II microdomains
in lysosome-like antigen processing compartments. When these
complexes arrive at the DC surface, they are visualized by both
immunoelectron microscopy and confocal microscopy to exist in
80 nm clusters (Fig. 3). The integrity of these MHC-II-HEL(46–61) clus-
ters is disrupted by MCD, suggesting that these clusters represent
newly arrived lipid raft-associated MHC-II-HEL(46–61) complexes
[16]. While there is much that we do not know about the organiza-
tion or molecular mechanisms stabilizing these structures on the
APC surface, the visualization of raft-associated clusters of identical
pMHC-II complexes is at least a beginning in our quest to understand
this process.
Fig. 1. Topological model of MHC-II movement from intraluminal vesicles of MVB to the plasmamembrane. MHC-II is present on lipid raft intraluminal vesicles (ILVs) with their peptide-
binding grooves exposed to the antigenic peptide-containing lumen of the MVB. A pMHC-II containing ILV (indicated by red membrane) moves toward the MVB limiting membrane
(step 1), docks with (step 2) and fuses with the limiting membrane (steps 3 & 4). Continued outward budding from the limiting membrane (step 5) leads to ILV ﬁssion from the limiting
membrane and release of a membrane-derived transport vesicle (step 6). This transport vesicle docks with the plasmamembrane (step 7) and the dockedmembranes fuse (steps 8 & 9),
thereby depositing a “MHC-II raft” generated from ILV membrane into the plasma membrane.
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Tetraspaninprotein familymembers contain four transmembranedo-
mains, intracellular amino and carboxy termini, and bind to a variety of
proteins to form the basis of the “tetraspanweb”. Just like the association
with lipid raft microdomains, the tetraspanweb is a relatively detergent-
insoluble membrane microdomain and associate with the tetraspan web
has been implicated in regulating a variety of biological events [39]. There
are many reports documenting the ability of MHC-II to the association
with different tetraspanin family members. The endosomal/lysosomal
tetraspanins CD81 and CD82 co-immunoprecipitate with MHC-II in
human B cell lines [40-42]. MHC-II associates with the CD63 in
endosomes and with CD9, CD53, and CD81 at the cell surface of DCs
[43]. MHC-II also associates with CD9 and CD38 in human monocytes
[22], with CD9, CD53, CD81, and CD82 in human DCs [42], and the asso-
ciation of CD9 with MHC-II has been reported to lead to clustering of
MHC-II on the surface of mouse DCs [44]. It has been proposed that
tetraspan web-association facilitates MHC-II clustering to form mem-
brane domains that are distinct from lipid rafts [45]. This study was
based on the use of a mAb that was proposed to recognize a subset of
tetraspanin-associated pMHC-II complexes [46]. A follow-up study didFig. 2.Model of MHC-II–Invariant chain complex-dependent pMHC-II concentration in lipid raf
domain (surroundedby the red border) containing large amounts of “relevant” antigenic peptid
are present in this samemicrodomain (center panel). Following CLIP removal byHLA-DM, sixM
(in yellow) that are all present within a single membrane microdomain (right panel).not ﬁnd any evidence that this mAb selectively recognized a subset of
MHC-II [42], calling into question the idea that MHC-II is differentially as-
sociated with either lipid raft or tetraspanin membrane microdomains.
In fact, a number of studies have indicated that tetraspanin mole-
cules can be isolated in detergent-insoluble fractions that, like lipid
rafts themselves, are cholesterol-dependent [47–49]. The tetraspanin-
web resident protein CD9 has also been reported to be a constituent in
“lipid rafts” isolated from activated eosinophil cells [50] and DCs [43].
Such studies suggest to us that the distinction between a detergent-
insoluble lipid raft microdomain and a tetraspanin microdomain is a
somewhat artiﬁcial one, and themost likely scenario is that tetraspanin
proteins, present in “lipid rafts”, help stabilize raft associations of
their binding partners (such as MHC-II) with these membrane
microdomains.
6. Importance of MHC-II lipid raft association for APC function
Each CD4 T cell contains a single T cell antigen receptor (TCR) spec-
iﬁcity that recognizes a combinatorial epitope containing both MHC-II
and its associated peptide fragment [51]. There are approximately 106
MHC-II molecules on professional APCs, however this number cants. TwoMHC-II αβ–Ii nonameric complexes are present in an ILV-derived lipid raft micro-
es (indicated in yellow, left panel). Following Ii degradation, sixMHC-IIαβ–CLIP complexes
HC-IIαβ–peptide complexes are formed that are enriched in “relevant” antigenic peptides
Fig. 3. Newly-arrived pMHC-II complexes are clustered on the DC surface. Immature DCs
were incubated with HEL protein, washed, and activated with LPS for 12 h. The DCs
were stained live with a mAb that only recognizes the I-Ak–HEL(46–61) complexes.
Aw3.18.14. The cells were analyzed by confocal immunoﬂuorescence microscopy and a
single 0.8 μm thick optical section is shown (left panel). The distribution of these
newly-arrived pMHC-II complexes on the DC surface was also determined using “plasma
membrane rips” and analysis by immunoelectron microscopy (right panel).
Reprinted with permission from reference [16].
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status. The pMHC-II repertoire is diverse and under normal conditions
the vast majority of MHC-II-bound peptides are derived from cellular
“self” proteins. During viral or microbial infections "foreign" (non-self)
MHC-II-bound peptides are recognized and responsible for antigen-
speciﬁc T cell activation. Less than 500 speciﬁc pMHC-II complexes are
required to activate antigen-speciﬁc naïve T cells [52,53] and this num-
ber may be lower for particular high-afﬁnity peptides. Even less pMHC-
II required to activate memory T cells, due to changes in the TCR oligo-
mers after responding to the original antigen [54]. These vanishingly
small amounts of speciﬁc pMHC-II on the APC surface (representing
less than0.01% of the total pool ofMHC-II)must somehowefﬁciently in-
teract with a single T cell, and we have proposed that MHC-II clustering
in lipid rafts is immunologically important since it increases the local
concentration of relevant pMHC-II complexes required to activate
antigen-speciﬁc CD4 T cells [17,28,55].
The ﬁrst evidence to suggest that APC lipid rafts are important for T
cell antigen recognition was the demonstration that treatment of
antigen-pulsed B cells with the cholesterol disrupting agents MCD or
nystatin signiﬁcantly reduced their ability to stimulate an antigen-
speciﬁc T cell hybridoma [17]. The suppressive effect of nystatin on
antigen-pulsed APC function was fully reversible, demonstrating that
cholesterol perturbation did not affect speciﬁc pMHC-II expression
levels or other factors necessary for efﬁcient T cell activation by APCs.
Curiously, raft disruption preferentially affected the APCs pulsed with
small amounts of antigen; raft disruption had no effect on T cell activa-
tion when the B cells were pulsed with large amounts of antigen [17].
The ability of lipid raft associated MHC-II to preferentially facilitate T
cell activation at low antigen concentration has now been observed in
a variety of systems including human DCs andmouse B cells presenting
inﬂuenza virus haemagglutinin epitopes to T cell clones [24,56] and
mouse DCs presenting HEL epitopes to naïve T cells [16]. The antigen-
dose dependence of MHC-II lipid raft association has been seen not
only when APCs were pulsed with intact protein antigens (which
require intracellular processing) but also when APCs were pulsed with
pre-processed antigenic peptides. that peptide-pulsing results in a “ho-
mogenous” distribution of pMHC-II on the APC surface, the ability of
APCs to internalize extracellular material (including peptides) by
macropinocytosis leaves open the possibility that even pre-processed
peptides bind primarily to intracellular (nascent) MHC-II. While this
possibility remains to be tested, the well-documented ability of
cholesterol-depletion to suppress T cell activation by APCs loadedwith limiting amounts of antigenic-peptides is entirely consistent with
the hypothesis that lipid raft association allows small numbers of specif-
ic pMHC-II to stimulate antigen-speciﬁc CD4 T cells.
7. MHC-II lipid rafts and T cell co-stimulation at the immunological
synapse
TCR recognition of pMHC-II complexes triggers a cascade of events
leading to the formation of a macromolecular complex between the
APC and T cell referred to as the immunological synapse [57]. The for-
mation of this structure triggers dramatic changes in the APC and T
cell membrane, ultimately resulting in T cell differentiation and acquisi-
tion of effector function. Imaging studies have shown that T cell lipid
rafts coalesce at the immunological synapse [58–60], with many T
cell-associated signaling molecules becoming raft-associated and
synapse-localized upon TCR engagement [58,61]. We have shown that
formation of an immunological synapse between antigen-loaded B
cells and antigen-speciﬁc T cells results in APC raft accumulation at
the immunological synapse [15]. T cell:APC conjugate formation also
leads to synaptic clustering of MHC-II that is both co-stimulation [62]
and ICAM-dependent [62,63]. Curiously, immunologically “relevant”
pMHC-II preferentially accumulates at the synapse under conditions of
low, but not high, antigen dose [15], suggesting that concentration of
pMHC-II at the synapse is important primarily when antigenic pMHC-
II amounts are limiting. These data are in excellent agreement with
data showing a concentration-dependent role for APC rafts in T cell
activation [16,17,24,56].
When the antigen-speciﬁc TCR recognizes relevant pMHC-II on DCs,
the maturing DCs respond by generating elongated MHC-II endo/
lysosomal tubules that emanate toward the immunologic synapse
[64,65] where they ultimately fuse with the plasma membrane [65].
The association of MHC-II with lipid rafts is likely to be critical for
this event since most of endosomal MHC-II in DCs is already raft-
associated [28] and any nascent MHC-II molecules are likely to load
with antigenic peptides derived from the pathogen (or antigen) that ini-
tially stimulated the DC. Thus, insertion of relevant pMHC-II directly
into the immunological synapse would enhance T cell signaling and
activation, a hallmark of efﬁcient antigen presentation.
Lipid rafts may also be involved in concentrating the APC co-
stimulatory molecules CD80, CD86, and CD40 at the immunological
synapse. CD40 weakly associates with MHC-II in resting B cells, and
either B cell activation or cross-linking with MHC-II or CD40 mAb
greatly increases their association [66]. Unlike MHC-II, only a small
portion of the total pool of CD40 is lipid raft associated in resting
APCs, but engagement of CD40 with CD40 ligand (CD154) dramati-
cally enhances CD40 clustering [67] and raft association [68,69]. Sim-
ilarly, shortly after CD40-mediated B cell activation total MHC-II and
CD80 cell surface expression remains unchanged but there is a rapid
increase in clustering of MHC-II with CD80 at the plasma membrane
that is blocked by cholesterol depletion [70]. In addition, CD86 and
MHC-II begin to co-localize in endosome-like vesicles in maturing
DCs, and upon full DC maturation these proteins co-localize exten-
sively on the APC surface in small clusters [71]. Although it is not
yet known whether these interactions are by direct protein–protein
interactions or are facilitated by their co-association with lipid rafts,
these studies raise the interesting possibility that one of the func-
tions of MHC-II lipid raft localization is to provide a lipid environ-
ment conducive to APC co-stimulatory protein concentration at the
developing immunological synapse.
8. Conclusion
Since the ﬁrst description of clustering of MHC-II on the surface of
APCs nearly 20 years ago, we have made great progress in understand-
ing the role that MHC-II microdomain association plays in APC function.
There are, however, considerable gaps in our knowledge, such as what
779H.A. Anderson, P.A. Roche / Biochimica et Biophysica Acta 1853 (2015) 775–780are the structural elements that regulate association of MHC-II with
lipid raft (or other) membrane microdomains, how can the reported
short life-time of lipid rafts be reconciled with extended stability of
MHC-II clusters on the APC surface, and whether/how the mechanisms
of peptide-binding onto MHC-II and MHC-II microdomain association
are linked. Undoubtedly these questions will be answered in the near
future and this information will give us a more clear understanding of
the wide variety of mechanisms that APCs use to interact with and
stimulate antigen-speciﬁc T cells.Acknowledgements
The work from the Roche laboratory cited in this review was sup-
ported by the Intramural Research Program of the National Cancer
Institute. H.A.A. is supported by the U.S. Food and Drug Administration.References
[1] K. Simons, J.L. Sampaio, Membrane organization and lipid rafts, Cold Spring Harb.
Perspect. Biol. 3 (2011) a004697.
[2] R.G. Anderson, K. Jacobson, A role for lipid shells in targeting proteins to caveolae,
rafts, and other lipid domains, Science 296 (2002) 1821–1825.
[3] M.F. Hanzal-Bayer, J.F. Hancock, Lipid rafts and membrane trafﬁc, FEBS Lett. 581
(2007) 2098–2104.
[4] V. Horejsi, M. Hrdinka, Membrane microdomains in immunoreceptor signaling,
FEBS Lett. 588 (2014) 2392–2397.
[5] D.A. Brown, J.K. Rose, Sorting of GPI-anchored proteins to glycolipid-enriched
membrane subdomains during transport to the apical cell surface, Cell 68 (1992)
533–544.
[6] S. Munro, Lipid rafts: elusive or illusive? Cell 115 (2003) 377–388.
[7] B. Nichols, Cell biology: without a raft, Nature 436 (2005) 638–639.
[8] K. Jacobson, O.G. Mouritsen, R.G. Anderson, Lipid rafts: at a crossroad between cell
biology and physics, Nat. Cell Biol. 9 (2007) 7–14.
[9] P. Keller, K. Simons, Cholesterol is required for surface transport of inﬂuenza virus
hemagglutinin, J. Cell Biol. 140 (1998) 1357–1367.
[10] J.S. Blum, P.A. Wearsch, P. Cresswell, Pathways of antigen processing, Annu. Rev.
Immunol. 31 (2013) 443–473.
[11] I. Chiu, D.M. Davis, J.L. Strominger, Trafﬁcking of spontaneously endocytosed MHC
proteins, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13944–13949.
[12] A. Jenei, S. Varga, L. Bene, L. Matyus, A. Bodnar, Z. Bacso, C. Pieri, R. Gaspar Jr., T.
Farkas, S. Damjanovich, HLA class I and II antigens are partially co-clustered in the
plasma membrane of human lymphoblastoid cells, Proc. Natl. Acad. Sci. U. S. A. 94
(1997) 7269–7274.
[13] G. Vereb, J. Matko, G. Vamosi, S.M. Ibrahim, E. Magyar, S. Varga, J. Szollosi, A. Jenei, R.
Gaspar Jr., T.A. Waldmann, S. Damjanovich, Cholesterol-dependent clustering of
IL-2Ralpha and its colocalization with HLA and CD48 on T lymphoma cells suggest
their functional association with lipid rafts, Proc. Natl. Acad. Sci. U. S. A. 97 (2000)
6013–6018.
[14] R.D. Huby, R.J. Dearman, I. Kimber, Intracellular phosphotyrosine induction bymajor
histocompatibility complex class II requires co-aggregation with membrane rafts, J.
Biol. Chem. 274 (1999) 22591–22596.
[15] E.M. Hiltbold, N.J. Poloso, P.A. Roche, MHC class II–peptide complexes and APC lipid
rafts accumulate at the immunological synapse, J. Immunol. 170 (2003) 1329–1338.
[16] B. Bosch, E.L. Heipertz, J.R. Drake, P.A. Roche, Major histocompatibility complex
(MHC) class II–peptide complexes arrive at the plasma membrane in cholesterol-
rich microclusters, J. Biol. Chem. 288 (2013) 13236–13242.
[17] H.A. Anderson, E.M. Hiltbold, P.A. Roche, Concentration of MHC class II molecules in
lipid rafts facilitates antigen presentation, Nat. Immunol. 1 (2000) 156–162.
[18] R. Knorr, C. Karacsonyi, R. Lindner, Endocytosis of MHC molecules by distinct mem-
brane rafts, J. Cell Sci. 122 (2009) 1584–1594.
[19] K. Busman-Sahay, E. Sargent, J.A. Harton, J.R. Drake, The Ia.2 epitope deﬁnes a subset
of lipid raft-resident MHC class II molecules crucial to effective antigen presentation,
J. Immunol. 186 (2011) 6710–6717.
[20] M. Bouillon, F.Y. El, J. Girouard, H. Khalil, J. Thibodeau, W. Mourad, Lipid raft-
dependent and -independent signaling through HLA-DR molecules, J. Biol. Chem.
278 (2003) 7099–7107.
[21] V. Buatois, M. Baillet, S. Becart, N. Mooney, L. Leserman, P. Machy, MHC class II–
peptide complexes in dendritic cell lipid microdomains initiate the CD4 Th1 pheno-
type, J. Immunol. 171 (2003) 5812–5819.
[22] M.T. Zilber, N. Setterblad, T. Vasselon, C. Doliger, D. Charron, N. Mooney, C. Gelin,
MHC class II/CD38/CD9: a lipid-raft-dependent signaling complex in human mono-
cytes, Blood 106 (2005) 3074–3081.
[23] N. Setterblad, C. Roucard, C. Bocaccio, J.P. Abastado, D. Charron, N. Mooney, Compo-
sition of MHC class II-enriched lipid microdomains is modiﬁed during maturation of
primary dendritic cells, J. Leukoc. Biol. 74 (2003) 40–48.
[24] E. Eren, J. Yates, K. Cwynarski, S. Preston, R. Dong, C. Germain, R. Lechler, R. Huby, M.
Ritter, G. Lombardi, Location of major histocompatibility complex class II molecules
in rafts on dendritic cells enhances the efﬁciency of T-cell activation and prolifera-
tion, Scand. J. Immunol. 63 (2006) 7–16.[25] S. Khandelwal, P.A. Roche, Distinct MHC class II molecules are associated on the den-
dritic cell surface in cholesterol-dependent membrane microdomains, J. Biol. Chem.
285 (2010) 35303–35310.
[26] E.B. Babiychuk, A. Draeger, Biochemical characterization of detergent-resistant
membranes: a systematic approach, Biochem. J. 397 (2006) 407–416.
[27] O. Bakke, B. Dobberstein, MHC class II-associated invariant chain contains a sorting
signal for endosomal compartments, Cell 63 (1990) 707–716.
[28] N.J. Poloso, A. Muntasell, P.A. Roche, MHC class II molecules trafﬁc into lipid rafts
during intracellular transport, J. Immunol. 173 (2004) 4539–4546.
[29] C. Karacsonyi, R. Knorr, A. Fulbier, R. Lindner, Association of major histocompatibility
complex II with cholesterol- and sphingolipid-rich membranes precedes peptide
loading, J. Biol. Chem. 279 (2004) 34818–34826.
[30] W. Mobius, E. van Donselaar, Y. Ohno-Iwashita, Y. Shimada, H.F. Heijnen, J.W. Slot, H.J.
Geuze, Recycling compartments and the internal vesicles of multivesicular bodies har-
bor most of the cholesterol found in the endocytic pathway, Trafﬁc 4 (2003) 222–231.
[31] R. Wubbolts, R.S. Leckie, P.T. Veenhuizen, G. Schwarzmann, W. Mobius, J.
Hoernschemeyer, J.W. Slot, H.J. Geuze, W. Stoorvogel, Proteomic and bio-
chemical analyses of human B cell-derived exosomes. Potential implications
for their function and multivesicular body formation, J. Biol. Chem. 278 (2003)
10963–10972.
[32] W. Mobius, Y. Ohno-Iwashita, E.G. van Donselaar, V.M. Oorschot, Y. Shimada, T.
Fujimoto, H.F. Heijnen, H.J. Geuze, J.W. Slot, Immunoelectron microscopic localiza-
tion of cholesterol using biotinylated and non-cytolytic perfringolysin O, J.
Histochem. Cytochem. 50 (2002) 43–55.
[33] M. Kleijmeer, G. Ramm, D. Schuurhuis, J. Grifﬁth, M. Rescigno, P. Ricciardi-
Castagnoli, A.Y. Rudensky, F. Ossendorp, C.J. Melief, W. Stoorvogel, H.J. Geuze,
Reorganization of multivesicular bodies regulates MHC class II antigen presentation
by dendritic cells, J. Cell Biol. 155 (2001) 53–63.
[34] P.D. Robbins, A.E. Morelli, Regulation of immune responses by extracellular vesicles,
Nat. Rev. Immunol. 14 (2014) 195–208.
[35] L. Zitvogel, A. Regnault, A. Lozier, J. Wolfers, C. Flament, D. Tenza, P. Ricciardi-
Castagnoli, G. Raposo, S. Amigorena, Eradication of established murine tumors
using a novel cell-free vaccine: dendritic cell-derived exosomes, Nat. Med. 4
(1998) 594–600.
[36] C. Thery, L. Duban, E. Segura, P. Veron, O. Lantz, S. Amigorena, Indirect activation of
naive CD4+ T cells by dendritic cell-derived exosomes, Nat. Immunol. 3 (2002)
1156–1162.
[37] A. Muntasell, A.C. Berger, P.A. Roche, T cell-induced secretion of MHC class II–
peptide complexes on B cell exosomes, EMBO J. 26 (2007) 4263–4272.
[38] P.A. Roche, M.S. Marks, P. Cresswell, Formation of a nine-subunit complex by HLA
class II glycoproteins and the invariant chain, Nature 354 (1991) 392–394.
[39] M.E. Hemler, Targeting of tetraspanin proteins—potential beneﬁts and strategies,
Nat. Rev. Drug Discov. 7 (2008) 747–758.
[40] C. Hammond, L.K. Denzin, M. Pan, J.M. Grifﬁth, H.J. Geuze, P. Cresswell, The tetraspan
protein CD82 is a resident of MHC class II compartments where it associates with
HLA-DR, -DM, and -DO molecules, J. Immunol. 161 (1998) 3282–3291.
[41] E. Rubinstein, F. LeNaour, C. Lagaudriere-Gesbert, M. Billard, H. Conjeaud, C.
Boucheix, CD9, CD63, CD81, and CD82 are components of a surface tetraspan net-
work connected to HLA-DR and VLA integrins, Eur. J. Immunol 26 (1996)
2657–2665.
[42] N.J. Poloso, L.K. Denzin, P.A. Roche, CDw78 deﬁnes MHC class II–peptide complexes
that require Ii chain-dependent lysosomal trafﬁcking, not localization to a speciﬁc
tetraspanin membrane microdomain, J. Immunol. 177 (2006) 5451–5458.
[43] A. Engering, J. Pieters, Association of distinct tetraspanins with MHC class II mole-
cules at different subcellular locations in human immature dendritic cells, Int.
Immunol. 13 (2001) 127–134.
[44] J.J. Unternaehrer, A. Chow, M. Pypaert, K. Inaba, I. Mellman, The tetraspanin CD9
mediates lateral association of MHC class II molecules on the dendritic cell surface,
Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 234–239.
[45] H. Kropshofer, S. Spindeldreher, T.A. Rohn, N. Platania, C. Grygar, N. Daniel, A.Wolpl,
H. Langen, V. Horejsi, A.B. Vogt, Tetraspan microdomains distinct from lipid rafts
enrich select peptide–MHC class II complexes, Nat. Immunol. 3 (2002) 61–68.
[46] K. Drbal, P. Angelisova, A.M. Rasmussen, I. Hilgert, S. Funderud, V. Horejsi, The
nature of the subset of MHC class II molecules carrying the CDw78 epitopes, Int.
Immunol. 11 (1999) 491–498.
[47] C. Claas, C.S. Stipp, M.E. Hemler, Evaluation of prototype transmembrane 4 super-
family protein complexes and their relation to lipid rafts, J. Biol. Chem. 276 (2001)
7974–7984.
[48] S. Charrin, S. Manie, C. Thiele, M. Billard, D. Gerlier, C. Boucheix, E. Rubinstein, A
physical and functional link between cholesterol and tetraspanins, Eur. J. Immunol.
33 (2003) 2479–2489.
[49] O. Silvie, S. Charrin, M. Billard, J.F. Franetich, K.L. Clark, G.J. van Gemert, R.W.
Sauerwein, F. Dautry, C. Boucheix, D. Mazier, E. Rubinstein, Cholesterol contributes
to the organization of tetraspanin-enriched microdomains and to CD81-dependent
infection by malaria sporozoites, J. Cell Sci. 119 (2006) 1992–2002.
[50] P. Akuthota, R.C. Melo, L.A. Spencer, P.F. Weller, MHC class II and CD9 in human
eosinophils localize to detergent-resistant membrane microdomains, Am. J. Respir.
Cell Mol. Biol. 46 (2012) 188–195.
[51] A.W. Goldrath, M.J. Bevan, Selecting and maintaining a diverse T-cell repertoire,
Nature 402 (1999) 255–262.
[52] C.V. Harding, E.R. Unanue, Quantitation of antigen-presenting cell MHC class
II/peptide complexes necessary for T-cell stimulation, Nature 346 (1990) 574–576.
[53] S. Demotz, H.M. Grey, A. Sette, The minimal number of class II MHC-antigen com-
plexes needed for T cell activation, Science 249 (1990) 1028–1030.
[54] R. Kumar, M. Ferez, M. Swamy, I. Arechaga, M.T. Rejas, J.M. Valpuesta, W.W.
Schamel, B. Alarcon, H.M. van Santen, Increased sensitivity of antigen-experienced
780 H.A. Anderson, P.A. Roche / Biochimica et Biophysica Acta 1853 (2015) 775–780T cells through the enrichment of oligomeric T cell receptor complexes, Immunity
35 (2011) 375–387.
[55] N.J. Poloso, P.A. Roche, Association of MHC class II–peptide complexes with plasma
membrane lipid microdomains, Curr. Opin. Immunol. 16 (2004) 103–107.
[56] I. Gombos, C. Detre, G. Vamosi, J. Matko, Rafting MHC-II domains in the APC
(presynaptic) plasmamembrane and the thresholds for T-cell activation and immu-
nological synapse formation, Immunol. Lett. 92 (2004) 117–124.
[57] M.L. Dustin, D. Depoil, New insights into the T cell synapse from single molecule
techniques, Nat. Rev. Immunol. 11 (2011) 672–684.
[58] P.W. Janes, S.C. Ley, A.I. Magee, Aggregation of lipid rafts accompanies signaling via
the T cell antigen receptor, J. Cell Biol. 147 (1999) 447–461.
[59] A. Viola, S. Schroeder, Y. Sakakibara, A. Lanzavecchia, T lymphocyte costimulation
mediated by reorganization of membrane microdomains [see comments], Science
283 (1999) 680–682.
[60] W.R. Burack, K.H. Lee, A.D. Holdorf, M.L. Dustin, A.S. Shaw, Cutting edge: quantita-
tive imaging of raft accumulation in the immunological synapse, J. Immunol. 169
(2002) 2837–2841.
[61] R. Xavier, T. Brennan, Q. Li, C. McCormack, B. Seed, Membrane compartmentation is
required for efﬁcient T cell activation, Immunity 8 (1998) 723–732.
[62] C. Wulﬁng, C. Sumen, M.D. Sjaastad, L.C. Wu, M.L. Dustin, M.M. Davis, Costimulation
and endogenous MHC ligands contribute to T cell recognition, Nat. Immunol. 3
(2002) 42–47.
[63] H. de la Fuente, M. Mittelbrunn, L. Sanchez-Martin, M. Vicente-Manzanares, A.
Lamana, R. Pardi, C. Cabanas, F. Sanchez-Madrid, Synaptic clusters of MHC class IImolecules induced on DCs by adhesion molecule-mediated initial T-cell scanning,
Mol. Biol. Cell 16 (2005) 3314–3322.
[64] M. Boes, J. Cerny, R. Massol, M. Op den Brouw, T. Kirchhausen, J. Chen, H.L. Ploegh,
T-cell engagement of dendritic cells rapidly rearranges MHC class II transport,
Nature 418 (2002) 983–988.
[65] A. Chow, D. Toomre, W. Garrett, I. Mellman, Dendritic cell maturation triggers retro-
grade MHC class II transport from lysosomes to the plasma membrane, Nature 418
(2002) 988–994.
[66] C. Leveille, F. Chandad, R. Al-Daccak, W. Mourad, CD40 associates with the MHC
class II molecules on human B cells, Eur. J. Immunol. 29 (1999) 3516–3526.
[67] H. Grassme, V. Jendrossek, J. Bock, A. Riehle, E. Gulbins, Ceramide-rich membrane
rafts mediate CD40 clustering, J. Immunol. 168 (2002) 298–307.
[68] B.S. Hostager, I.M. Catlett, G.A. Bishop, Recruitment of CD40 and tumor necrosis
factor receptor-associated factors 2 and 3 to membrane microdomains during
CD40 signaling, J. Biol. Chem. 275 (2000) 15392–15398.
[69] A. Nadiri, M.J. Polyak, M. Jundi, H. Alturaihi, C. Reyes-Moreno, G.S. Hassan, W.
Mourad, CD40 translocation to lipid rafts: signaling requirements and downstream
biological events, Eur. J. Immunol. 41 (2011) 2358–2367.
[70] A. Clatza, L.C. Bonifaz, D.A. Vignali, J. Moreno, CD40-induced aggregation of MHC
class II and CD80 on the cell surface leads to an early enhancement in antigen pre-
sentation, J. Immunol. 171 (2003) 6478–6487.
[71] S.J. Turley, K. Inaba, W.S. Garrett, M. Ebersold, J. Unternaehrer, R.M. Steinman, I.
Mellman, Transport of peptide–MHC class II complexes in developing dendritic
cells, Science 288 (2000) 522–527.
